A world-first randomised clinical trial in men with paedophilic disorder shows that a dose of degarelix acetate may reduce their risk factors for committing child sexual abuse within two weeks.

In the landmark Swedish trial, 53 men (mean age 36 years) were randomised either to 240mg subcutaneous injection of the gonadotropin-releasing hormone antagonist, which is indicated for androgen deprivation therapy in prostate cancer, or to placebo injection.